铁灭激活癌症治疗中Nrf2信号的调节和功能
Xin Jiang1, Min Yu2, Wei-Kai Wang1
1Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
Acta pharmacologica Sinica
|July 17, 2024
概括
铁灭,细胞死亡过程,在癌症治疗中至关重要. 与核因子E2相关的因子2 (Nrf2) 以及铁灭激活剂一起向核因子E2,可以克服癌细胞抵抗力并提高治疗疗效.
科学领域:
- 生物化学和分子生物学
- 癌症生物学 癌症生物学
- 细胞死亡机制 细胞死亡机制
背景情况:
- 铁亡是一种依赖于铁的编程细胞死亡,涉及脂质过氧化,与癌症发生和治疗反应有关.
- 癌细胞通过调节氧化应激路径来对铁亡产生抵抗力,从而限制了治疗疗效.
- 核因子E2相关因子2 (Nrf2) 是一个关键的转录因子,调节抗氧化系统和铁亡.
研究的目的:
- 审查Nrf2信号调节和功能在铁灭激活癌症治疗中的最新进展.
- 探索将Nrf2抑制剂与铁灭诱导剂结合用于癌症治疗的潜力.
主要方法:
- 文献综述总结了关于Nrf2信号和铁亡的当前研究.
- 分析Nrf2在与铁,谷氨过氧化酶4 (GPX4) 和抗氧化系统相关的细胞网络重编程中的作用.
- 探索针对Nrf2-ferroptosis轴的治疗策略.
主要成果:
- Nrf2通过重编程关键的细胞防御网络,在减弱铁亡中发挥主导作用.
- 癌细胞对铁亡的抵抗与Nrf2介导的适应性反应有关.
- 准Nrf2信号对于增强基于铁亡的癌症疗法至关重要.
结论:
- Nrf2信号显著影响铁,是癌症治疗的关键标.
- 将Nrf2抑制剂与铁灭诱导剂相结合,为克服治疗耐药性和改善癌症治疗结果提供了一个有希望的策略.
更多相关视频
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
Electron Transport Chain: Complex I and II
12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K


